skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy

International journal of molecular sciences, 2019-02, Vol.20 (3), p.755 [Peer Reviewed Journal]

2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 by the authors. 2019 ;ISSN: 1422-0067 ;ISSN: 1661-6596 ;EISSN: 1422-0067 ;DOI: 10.3390/ijms20030755 ;PMID: 30754640

Full text available

Citations Cited by
  • Title:
    mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
  • Author: Tian, Tian ; Li, Xiaoyi ; Zhang, Jinhua
  • Subjects: cancer ; Cancer therapies ; Head & neck cancer ; inhibitor ; Kinases ; Metastasis ; mTOR ; Patients ; PI3K ; Review ; therapy
  • Is Part Of: International journal of molecular sciences, 2019-02, Vol.20 (3), p.755
  • Description: The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in regulation of cell survival, metabolism, growth and protein synthesis in response to upstream signals in both normal physiological and pathological conditions, especially in cancer. Aberrant mTOR signaling resulting from genetic alterations from different levels of the signal cascade is commonly observed in various types of cancers. Upon hyperactivation, mTOR signaling promotes cell proliferation and metabolism that contribute to tumor initiation and progression. In addition, mTOR also negatively regulates autophagy via different ways. We discuss mTOR signaling and its key upstream and downstream factors, the specific genetic changes in the mTOR pathway and the inhibitors of mTOR applied as therapeutic strategies in eight solid tumors. Although monotherapy and combination therapy with mTOR inhibitors have been extensively applied in preclinical and clinical trials in various cancer types, innovative therapies with better efficacy and less drug resistance are still in great need, and new biomarkers and deep sequencing technologies will facilitate these mTOR targeting drugs benefit the cancer patients in personalized therapy.
  • Publisher: Switzerland: MDPI AG
  • Language: English
  • Identifier: ISSN: 1422-0067
    ISSN: 1661-6596
    EISSN: 1422-0067
    DOI: 10.3390/ijms20030755
    PMID: 30754640
  • Source: PubMed Central
    ProQuest Central
    DOAJ Directory of Open Access Journals
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait